glp-1 news nov 2025 november Agonists Market Report 2025-2033, By Product, Molecule, and Geo glp-1 news november 2025 ISPOR – GLP-1R Race in 2025: 8

Valvular heart disease associated with fenfluramine-phentermine

Interestingly, about half of users stop taking these medications within a year, a dropout rate similar to lifestyle programs

Adding NAD+ supplementation to a GLP-1 protocol without measuring baseline NAD+ levels is, by the standards of that same engagement, a gap

The timing of GLP-1 administration may influence the tolerability of these symptoms, though this has not been definitively established in clinical trials

GLP-1 receptor agonists in obese patients with inflammatory bowel disease: from molecular mechanisms to clinical considerations and practical recommendations for safe and effective use

The decision to initiate pharmacotherapy requires shared decision-making, discussing realistic expectations, potential adverse effects, cost considerations, and the likely need for indefinite treatment duration